Lemontart的个人主页 - 老虎社区

Lemontart

Lemontart

暂无个人介绍

IP属地：未知

1关注

6粉丝

0主题

0勋章

2021-11-24

$Novavax(NVAX)$woohoo novavax files for interim authorization in Singapore!!

2021-11-01

$Novavax(NVAX)$Awesome. Heard Stan is on Bloomberg giving an interview update :)

2021-10-21

Ooh

抱歉，原内容已删除

2021-09-29

Ok

抱歉，原内容已删除

2021-09-29

Sigh

抱歉，原内容已删除

2021-09-29

Ok

抱歉，原内容已删除

2021-09-29

Oh dear

Why Pfizer, BioNTech, Moderna, and Novavax Stocks Are Falling Tuesday

2021-09-28

Ok

抱歉，原内容已删除

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":4087299128031090,"uuid":"4087299128031090","gmtCreate":1624196065176,"gmtModify":1631153056152,"name":"Lemontart","pinyin":"lemontart","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/9928a331ddd0127bcf6dfc6e8becce27","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":6,"headSize":1,"tweetSize":9,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.11.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"35ec162348d5460f88c959321e554969-1","templateUuid":"35ec162348d5460f88c959321e554969","name":"精英交易员","description":"证券或期货账户累计交易次数达到30次","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.05.19","exceedPercentage":"60.64%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":3,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":4,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":874858354,"gmtCreate":1637761173275,"gmtModify":1637761173329,"author":{"id":"4087299128031090","authorId":"4087299128031090","name":"Lemontart","avatar":"https://static.tigerbbs.com/9928a331ddd0127bcf6dfc6e8becce27","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NVAX\">$Novavax(NVAX)$</a>woohoo novavax files for interim authorization in Singapore!!&nbsp;","listText":"<a href=\"https://laohu8.com/S/NVAX\">$Novavax(NVAX)$</a>woohoo novavax files for interim authorization in Singapore!!&nbsp;","text":"$Novavax(NVAX)$woohoo novavax files for interim authorization in Singapore!!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":10,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/874858354","isVote":1,"tweetType":1,"viewCount":1271,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":843011600,"gmtCreate":1635781904266,"gmtModify":1635793531471,"author":{"id":"4087299128031090","authorId":"4087299128031090","name":"Lemontart","avatar":"https://static.tigerbbs.com/9928a331ddd0127bcf6dfc6e8becce27","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NVAX\">$Novavax(NVAX)$</a>Awesome. Heard Stan is on Bloomberg giving an interview update :)","listText":"<a href=\"https://laohu8.com/S/NVAX\">$Novavax(NVAX)$</a>Awesome. Heard Stan is on Bloomberg giving an interview update :)","text":"$Novavax(NVAX)$Awesome. Heard Stan is on Bloomberg giving an interview update :)","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/843011600","isVote":1,"tweetType":1,"viewCount":642,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":853576861,"gmtCreate":1634826968415,"gmtModify":1634827250130,"author":{"id":"4087299128031090","authorId":"4087299128031090","name":"Lemontart","avatar":"https://static.tigerbbs.com/9928a331ddd0127bcf6dfc6e8becce27","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Ooh","listText":"Ooh","text":"Ooh","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/853576861","repostId":"1171915283","repostType":2,"isVote":1,"tweetType":1,"viewCount":451,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":862231277,"gmtCreate":1632880318766,"gmtModify":1632880318766,"author":{"id":"4087299128031090","authorId":"4087299128031090","name":"Lemontart","avatar":"https://static.tigerbbs.com/9928a331ddd0127bcf6dfc6e8becce27","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/862231277","repostId":"1121775545","repostType":4,"isVote":1,"tweetType":1,"viewCount":445,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":862665790,"gmtCreate":1632876324299,"gmtModify":1632876324299,"author":{"id":"4087299128031090","authorId":"4087299128031090","name":"Lemontart","avatar":"https://static.tigerbbs.com/9928a331ddd0127bcf6dfc6e8becce27","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Sigh&nbsp;","listText":"Sigh&nbsp;","text":"Sigh","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/862665790","repostId":"1129273771","repostType":2,"isVote":1,"tweetType":1,"viewCount":561,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":862666435,"gmtCreate":1632876245900,"gmtModify":1632876245900,"author":{"id":"4087299128031090","authorId":"4087299128031090","name":"Lemontart","avatar":"https://static.tigerbbs.com/9928a331ddd0127bcf6dfc6e8becce27","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Ok&nbsp;","listText":"Ok&nbsp;","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/862666435","repostId":"1104845344","repostType":2,"isVote":1,"tweetType":1,"viewCount":776,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":862666377,"gmtCreate":1632876223234,"gmtModify":1632876223234,"author":{"id":"4087299128031090","authorId":"4087299128031090","name":"Lemontart","avatar":"https://static.tigerbbs.com/9928a331ddd0127bcf6dfc6e8becce27","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Oh dear","listText":"Oh dear","text":"Oh dear","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/862666377","repostId":"1111572816","repostType":2,"repost":{"id":"1111572816","pubTimestamp":1632875079,"share":"https://www.laohu8.com/m/news/1111572816?lang=&edition=full","pubTime":"2021-09-29 08:24","market":"us","language":"en","title":"Why Pfizer, BioNTech, Moderna, and Novavax Stocks Are Falling Tuesday","url":"https://stock-news.laohu8.com/highlight/detail?id=1111572816","media":"Motley Fool","summary":"Investors seem increasingly jittery about the future prospects for COVID-19 vaccines.\n\nKey Points\n\nP","content":"<blockquote>\n <b><a href=\"https://laohu8.com/S/ISBC\">Investors</a> seem increasingly jittery about the future prospects for COVID-19 vaccines.</b>\n</blockquote>\n<p><b>Key <a href=\"https://laohu8.com/S/PCOM\">Points</a></b></p>\n<ul>\n <li><a href=\"https://laohu8.com/S/PFE\">Pfizer</a>, <a href=\"https://laohu8.com/S/BNTX\">BioNTech SE</a>, and <a href=\"https://laohu8.com/S/NVAX\">Novavax</a> had some good news Tuesday.</li>\n <li>Vaccine stocks are falling, though, probably because of uncertainty about future demand for vaccines.</li>\n <li>It's still possible that coronavirus variants could drive sustained demand for COVID-19 vaccines.</li>\n</ul>\n<p><b>What happened</b></p>\n<p>This isn't shaping up to be a good week for the stocks of leading COVID-19 vaccine makers. Several of the stocksslipped on Monday. The downtrend continued Tuesday.</p>\n<p>Shares of<b>Pfizer</b>(NYSE:PFE)were down 1.6% at 11:27 a.m.<b>BioNTech</b>(NASDAQ:BNTX)stock had fallen 9.4%.<b>Moderna</b>'s(NASDAQ:MRNA)shares were 6.2% lower.<b>Novavax</b>(NASDAQ:NVAX)was an especially big loser, its shares having sunk 11.6%.</p>\n<p>The declines for these&nbsp;vaccine stocks&nbsp;came despite some good news for several of them. Pfizer and BioNTech submitted initial data to the U.S. Food and Drug Administration from a late-stage study of their COVID-19 vaccine in children younger than 12 years down to age 5. Indian regulators also allowed the Serum Institute of India to begin enrolling kids ages 7 to 11 in a clinical trial evaluating Novavax's COVID-19 vaccine.</p>\n<p>So why are the stocks falling Tuesday? It's probably because investors are becoming increasingly anxious about the prospects for COVID-19 vaccine sales. The CEOs of both Pfizer and Moderna recently predicted thatthe pandemic could end in 2022.</p>\n<p>Also, Pfizer announced on Monday that it's started testing a pill that could be used to prevent infection after exposure to another person with COVID-19. If Pfizer's oral drug or similar antiviral therapies become available, it could reduce the incentive for people to seek vaccination.</p>\n<p><b>So what</b></p>\n<p>Investors absolutely should be looking to the future to evaluate the prospects for vaccine stocks. And there is uncertainty as to whether COVID-19 vaccine sales will remain as strong as they are now in 2023 and beyond.</p>\n<p>It's not surprising that Pfizer stock didn't fall nearly as much as shares of BioNTech, Moderna, or Novavax. The big drugmaker isn't totally dependent on its COVID-19 vaccine, as BioNTech and Moderna are -- and Novavax potentially soon will be.</p>\n<p>However, there's still a possibility that emerging coronavirus variants could cause the demand for COVID-19 vaccines to remain strong for years to come. Tuesday's sell-off could turn out to be unwarranted.</p>\n<p><b>Now what</b></p>\n<p>Each of these stocks has key catalysts on the way. Pfizer and BioNTech hope to soon file for FDA Emergency Use Authorization for their COVID-19 vaccine in immunizing younger children. Moderna awaits a decision on booster doses. Novavax hopes to win Emergency Use Listing from the World Health Organization for its COVID-19 vaccine and plans to file for EUAs in multiple countries.</p>\n<p>As long as the uncertainty about future demand for COVID-19 vaccines continues, though, look for continued volatility with all of these stocks.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Pfizer, BioNTech, Moderna, and Novavax Stocks Are Falling Tuesday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Pfizer, BioNTech, Moderna, and Novavax Stocks Are Falling Tuesday\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-29 08:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/28/why-pfizer-biontech-moderna-and-novavax-stocks-are/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Investors seem increasingly jittery about the future prospects for COVID-19 vaccines.\n\nKey Points\n\nPfizer, BioNTech SE, and Novavax had some good news Tuesday.\nVaccine stocks are falling, though, ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/28/why-pfizer-biontech-moderna-and-novavax-stocks-are/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","NVAX":"诺瓦瓦克斯医药","BNTX":"BioNTech SE","MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2021/09/28/why-pfizer-biontech-moderna-and-novavax-stocks-are/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1111572816","content_text":"Investors seem increasingly jittery about the future prospects for COVID-19 vaccines.\n\nKey Points\n\nPfizer, BioNTech SE, and Novavax had some good news Tuesday.\nVaccine stocks are falling, though, probably because of uncertainty about future demand for vaccines.\nIt's still possible that coronavirus variants could drive sustained demand for COVID-19 vaccines.\n\nWhat happened\nThis isn't shaping up to be a good week for the stocks of leading COVID-19 vaccine makers. Several of the stocksslipped on Monday. The downtrend continued Tuesday.\nShares ofPfizer(NYSE:PFE)were down 1.6% at 11:27 a.m.BioNTech(NASDAQ:BNTX)stock had fallen 9.4%.Moderna's(NASDAQ:MRNA)shares were 6.2% lower.Novavax(NASDAQ:NVAX)was an especially big loser, its shares having sunk 11.6%.\nThe declines for these vaccine stocks came despite some good news for several of them. Pfizer and BioNTech submitted initial data to the U.S. Food and Drug Administration from a late-stage study of their COVID-19 vaccine in children younger than 12 years down to age 5. Indian regulators also allowed the Serum Institute of India to begin enrolling kids ages 7 to 11 in a clinical trial evaluating Novavax's COVID-19 vaccine.\nSo why are the stocks falling Tuesday? It's probably because investors are becoming increasingly anxious about the prospects for COVID-19 vaccine sales. The CEOs of both Pfizer and Moderna recently predicted thatthe pandemic could end in 2022.\nAlso, Pfizer announced on Monday that it's started testing a pill that could be used to prevent infection after exposure to another person with COVID-19. If Pfizer's oral drug or similar antiviral therapies become available, it could reduce the incentive for people to seek vaccination.\nSo what\nInvestors absolutely should be looking to the future to evaluate the prospects for vaccine stocks. And there is uncertainty as to whether COVID-19 vaccine sales will remain as strong as they are now in 2023 and beyond.\nIt's not surprising that Pfizer stock didn't fall nearly as much as shares of BioNTech, Moderna, or Novavax. The big drugmaker isn't totally dependent on its COVID-19 vaccine, as BioNTech and Moderna are -- and Novavax potentially soon will be.\nHowever, there's still a possibility that emerging coronavirus variants could cause the demand for COVID-19 vaccines to remain strong for years to come. Tuesday's sell-off could turn out to be unwarranted.\nNow what\nEach of these stocks has key catalysts on the way. Pfizer and BioNTech hope to soon file for FDA Emergency Use Authorization for their COVID-19 vaccine in immunizing younger children. Moderna awaits a decision on booster doses. Novavax hopes to win Emergency Use Listing from the World Health Organization for its COVID-19 vaccine and plans to file for EUAs in multiple countries.\nAs long as the uncertainty about future demand for COVID-19 vaccines continues, though, look for continued volatility with all of these stocks.","news_type":1},"isVote":1,"tweetType":1,"viewCount":364,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":866402080,"gmtCreate":1632794249540,"gmtModify":1632797571533,"author":{"id":"4087299128031090","authorId":"4087299128031090","name":"Lemontart","avatar":"https://static.tigerbbs.com/9928a331ddd0127bcf6dfc6e8becce27","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/866402080","repostId":"1121775545","repostType":4,"isVote":1,"tweetType":1,"viewCount":469,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":874858354,"gmtCreate":1637761173275,"gmtModify":1637761173329,"author":{"id":"4087299128031090","authorId":"4087299128031090","name":"Lemontart","avatar":"https://static.tigerbbs.com/9928a331ddd0127bcf6dfc6e8becce27","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NVAX\">$Novavax(NVAX)$</a>woohoo novavax files for interim authorization in Singapore!!&nbsp;","listText":"<a href=\"https://laohu8.com/S/NVAX\">$Novavax(NVAX)$</a>woohoo novavax files for interim authorization in Singapore!!&nbsp;","text":"$Novavax(NVAX)$woohoo novavax files for interim authorization in Singapore!!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":10,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/874858354","isVote":1,"tweetType":1,"viewCount":1271,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":843011600,"gmtCreate":1635781904266,"gmtModify":1635793531471,"author":{"id":"4087299128031090","authorId":"4087299128031090","name":"Lemontart","avatar":"https://static.tigerbbs.com/9928a331ddd0127bcf6dfc6e8becce27","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NVAX\">$Novavax(NVAX)$</a>Awesome. Heard Stan is on Bloomberg giving an interview update :)","listText":"<a href=\"https://laohu8.com/S/NVAX\">$Novavax(NVAX)$</a>Awesome. Heard Stan is on Bloomberg giving an interview update :)","text":"$Novavax(NVAX)$Awesome. Heard Stan is on Bloomberg giving an interview update :)","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/843011600","isVote":1,"tweetType":1,"viewCount":642,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":862665790,"gmtCreate":1632876324299,"gmtModify":1632876324299,"author":{"id":"4087299128031090","authorId":"4087299128031090","name":"Lemontart","avatar":"https://static.tigerbbs.com/9928a331ddd0127bcf6dfc6e8becce27","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Sigh&nbsp;","listText":"Sigh&nbsp;","text":"Sigh","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/862665790","repostId":"1129273771","repostType":2,"repost":{"id":"1129273771","pubTimestamp":1632874854,"share":"https://www.laohu8.com/m/news/1129273771?lang=&edition=full","pubTime":"2021-09-29 08:20","market":"us","language":"en","title":"We Are Entering The Most Aggressive Global Hiking Cycle In A Decade","url":"https://stock-news.laohu8.com/highlight/detail?id=1129273771","media":"zerohedge","summary":"Maybe the market has been too hypnotized by the promise of cheap free money flowing forever, or mayb","content":"<p>Maybe the market has been too hypnotized by the promise of cheap free money flowing forever, or maybe it remembers how the Fed stepped in last March to ensure that nobody lost any money and thus nobody wants to sell this time, or maybe it is just too used to buying every single dip so that news of the Fed's taper actually sent stocks higher. But all that may soon change, because as Deutsche Bank's Jim Reid calculates in terms of global central bank hikes exceeding cuts, we are now at the highest differential for a decade on a rolling 12-month basis.</p>\n<p>In other words,<i>we are now entering the most aggressively global hiking cycle in a decade.</i></p>\n<p>Some points on the data:</p>\n<ul>\n <li>The last 12 months have actually seen a historically low number of central bank rate moves in either direction. Never have global central banks been so inactive on that score. This is now starting to pick up though.</li>\n <li>Since May 2012, global central banks have only seen the rolling 12m hike totals exceed cuts on 10% of occasions. We have just entered such a net hiking zone.</li>\n <li>Central bank cuts have overwhelming exceeded hikes over the last couple of decades.</li>\n</ul>\n<p><img src=\"https://static.tigerbbs.com/d2760bc2328e86bf9439b7c268c2bd94\" tg-width=\"814\" tg-height=\"289\" width=\"100%\" height=\"auto\"></p>\n<p>So its quite clear that a global hiking cycle had already started before the recent mini energy crisis. Will this renewed spike in energy costs mean central banks accelerate this (e.g. BoE guidance last week) or will it hit demand enough that it actually slows them down as stocks slide?</p>\n<p>The answer is unclear but as Reid concludes, \"this is an incredibly delicate and difficult period for central banks.\"&nbsp; As a minimum, Reid notes, rates markets are finally waking up to the asymmetric risk/reward that had developed over the summer months given all the global inflation in the system and the evidence that we were in a global hiking cycle. One wonders when stocks will do the same.</p>","source":"lsy1583725640930","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>We Are Entering The Most Aggressive Global Hiking Cycle In A Decade</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWe Are Entering The Most Aggressive Global Hiking Cycle In A Decade\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-29 08:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.zerohedge.com/markets/we-are-entering-most-aggressive-global-hiking-cycle-decade><strong>zerohedge</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Maybe the market has been too hypnotized by the promise of cheap free money flowing forever, or maybe it remembers how the Fed stepped in last March to ensure that nobody lost any money and thus ...</p>\n\n<a href=\"https://www.zerohedge.com/markets/we-are-entering-most-aggressive-global-hiking-cycle-decade\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite",".DJI":"道琼斯",".SPX":"S&P 500 Index","SPY":"标普500ETF"},"source_url":"https://www.zerohedge.com/markets/we-are-entering-most-aggressive-global-hiking-cycle-decade","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1129273771","content_text":"Maybe the market has been too hypnotized by the promise of cheap free money flowing forever, or maybe it remembers how the Fed stepped in last March to ensure that nobody lost any money and thus nobody wants to sell this time, or maybe it is just too used to buying every single dip so that news of the Fed's taper actually sent stocks higher. But all that may soon change, because as Deutsche Bank's Jim Reid calculates in terms of global central bank hikes exceeding cuts, we are now at the highest differential for a decade on a rolling 12-month basis.\nIn other words,we are now entering the most aggressively global hiking cycle in a decade.\nSome points on the data:\n\nThe last 12 months have actually seen a historically low number of central bank rate moves in either direction. Never have global central banks been so inactive on that score. This is now starting to pick up though.\nSince May 2012, global central banks have only seen the rolling 12m hike totals exceed cuts on 10% of occasions. We have just entered such a net hiking zone.\nCentral bank cuts have overwhelming exceeded hikes over the last couple of decades.\n\n\nSo its quite clear that a global hiking cycle had already started before the recent mini energy crisis. Will this renewed spike in energy costs mean central banks accelerate this (e.g. BoE guidance last week) or will it hit demand enough that it actually slows them down as stocks slide?\nThe answer is unclear but as Reid concludes, \"this is an incredibly delicate and difficult period for central banks.\"  As a minimum, Reid notes, rates markets are finally waking up to the asymmetric risk/reward that had developed over the summer months given all the global inflation in the system and the evidence that we were in a global hiking cycle. One wonders when stocks will do the same.","news_type":1},"isVote":1,"tweetType":1,"viewCount":561,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":862666377,"gmtCreate":1632876223234,"gmtModify":1632876223234,"author":{"id":"4087299128031090","authorId":"4087299128031090","name":"Lemontart","avatar":"https://static.tigerbbs.com/9928a331ddd0127bcf6dfc6e8becce27","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Oh dear","listText":"Oh dear","text":"Oh dear","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/862666377","repostId":"1111572816","repostType":2,"isVote":1,"tweetType":1,"viewCount":364,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":866402080,"gmtCreate":1632794249540,"gmtModify":1632797571533,"author":{"id":"4087299128031090","authorId":"4087299128031090","name":"Lemontart","avatar":"https://static.tigerbbs.com/9928a331ddd0127bcf6dfc6e8becce27","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/866402080","repostId":"1121775545","repostType":4,"isVote":1,"tweetType":1,"viewCount":469,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":853576861,"gmtCreate":1634826968415,"gmtModify":1634827250130,"author":{"id":"4087299128031090","authorId":"4087299128031090","name":"Lemontart","avatar":"https://static.tigerbbs.com/9928a331ddd0127bcf6dfc6e8becce27","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Ooh","listText":"Ooh","text":"Ooh","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/853576861","repostId":"1171915283","repostType":2,"repost":{"id":"1171915283","pubTimestamp":1634817585,"share":"https://www.laohu8.com/m/news/1171915283?lang=&edition=full","pubTime":"2021-10-21 19:59","market":"us","language":"en","title":"7 Reasons Why Novavax Is a No-Brainer Pick Over Ocugen","url":"https://stock-news.laohu8.com/highlight/detail?id=1171915283","media":"Motley Fool","summary":"There's no contest between the stock performances of Novavax(NASDAQ:NVAX)and Ocugen(NASDAQ:OCGN)so f","content":"<p>There's no contest between the stock performances of&nbsp;<b>Novavax</b>(NASDAQ:NVAX)and&nbsp;<b>Ocugen</b>(NASDAQ:OCGN)so far this year. Ocugen's share price has skyrocketed roughly seven times more than Novavax's has.</p>\n<p>Does that make Ocugen the smarter&nbsp;vaccine stock&nbsp;to buy right now? Not at all. Here are seven reasons why Novavax stock is a no-brainer pick over Ocugen.</p>\n<p>1. A path to EUA in the U.S.</p>\n<p>Ocugen's share price skyrocketed more than 750% year to date twice in 2021. But much of that massive gain evaporated after the company disclosed in June that it would no longer pursue Emergency Use Authorization (EUA) in the U.S. for COVID-19 vaccine Covaxin.</p>\n<p>The company opted to go for full approval once the U.S. Food and Drug Administration limited which vaccines would be reviewed under the EUA program. So far, however, Ocugen hasn't begun the late-stage clinical studies that will be required to win full FDA approval.</p>\n<p>Meanwhile, Novavax still has U.S. EUA for its COVID-19 vaccine candidate NVX-CoV2373 as a top priority. The company will be&nbsp;later than it hoped in filing for authorization in the U.S.However, it has the potential to launch in the U.S. much sooner than Ocugen could.</p>\n<p>Ocugen still hopes to obtain authorization for Covaxin in Canada. But the U.S. stands as the big prize. And it's a prize for which Novavax clearly has a better opportunity right now.</p>\n<p>2. Supply deals already in hand</p>\n<p>Some investors focus entirely on the approval or authorization process for COVID-19 vaccines. Without supply agreements in place with at least one country, though, any regulatory wins will be hollow victories.</p>\n<p>Ocugen doesn't have any supply deals finalized yet. Novavax, on the other hand, already has supply deals in place with the U.S., Canada, the EU, Australia, New Zealand, Japan (through its partner,<b>Takeda</b>), and Gavi, the Vaccine Alliance.</p>\n<p>3. Full rights to its COVID-19 vaccine</p>\n<p>Ocugen secured commercialization rights from Bharat Biotech for Covaxin only in the U.S. and Canada. Its terms with Bharat allow the company to keep 45% of the profits from any sales of the COVID-19 vaccine in those two markets.</p>\n<p>Novavax developed NVX-CoV2373 on its own. It retains full rights to the vaccine, although it has partnered with other organizations to target some markets.</p>\n<p>4. A stronger pipeline</p>\n<p>Other than Covaxin, Ocugen doesn't have any other pipeline candidates currently in clinical testing. The company has stated that it plans to advance experimental gene therapy OCU400 into two phase 1/2a clinical trials in 2021, but those studies haven't begun yet.</p>\n<p>Novavax has already reported positive results from a phase 3 study of flu vaccine candidate NanoFlu. It kicked off a phase 1/2 study evaluating a combination of NVX-CoV2373 and NanoFlu in September. The company also has two other clinical-stage candidates -- respiratory syncytial virus vaccine ResVax and an Ebola virus vaccine.</p>\n<p>5. More cash</p>\n<p>Cash is extremely important to clinical-stage biotechs. Without enough cash, they can be forced to raise capital to fund operations and expensive clinical trials through dilutive stock offerings.</p>\n<p>As of June 30, 2021, Ocugen's cash, cash equivalents, and restricted cash totaled $115.8 million. Novavax's cash stockpile stood at $2.1 billion as of the same date.</p>\n<p>6. More potential near-term catalysts</p>\n<p>Ocugen really has only one solid potential near-term catalyst: It's awaiting a decision by Health Canada on the authorization of Covaxin. Any wins for the vaccine outside of Canada or the U.S. benefit Bharat but not Ocugen.</p>\n<p>What about Novavax? The company hopes to soon win EUAs in India, Indonesia, and the Philippines. Novavax is awaiting Emergency Use Listing from the World Health Organization for NVX-CoV2373. It's also moving toward regulatory filings in the U.K., Europe, Australia, Canada, New Zealand, and the U.S.</p>\n<p>7. A more defensible valuation</p>\n<p>Ocugen's impressive performance so far this year has stemmed in large part from the combination of intense online interest and a large number of shares sold short. This makes the stock a good candidate for ashort squeeze. But the company's market cap tops $1.6 billion with analysts expecting Ocugen to only generate around $135 million in revenue next year.</p>\n<p>Novavax, though, could soon see big bucks flowing in if it wins authorizations and approvals for NVX-CoV2373. The company's market cap stands near $12.4 billion. However, with anticipated revenue of $5.5 billion in 2022, that valuation is much more defensible than Ocugen's is.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>7 Reasons Why Novavax Is a No-Brainer Pick Over Ocugen</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n7 Reasons Why Novavax Is a No-Brainer Pick Over Ocugen\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-21 19:59 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/10/21/7-reasons-why-novavax-is-a-no-brainer-pick-over-oc/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>There's no contest between the stock performances of Novavax(NASDAQ:NVAX)and Ocugen(NASDAQ:OCGN)so far this year. Ocugen's share price has skyrocketed roughly seven times more than Novavax's has.\nDoes...</p>\n\n<a href=\"https://www.fool.com/investing/2021/10/21/7-reasons-why-novavax-is-a-no-brainer-pick-over-oc/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen","NVAX":"诺瓦瓦克斯医药"},"source_url":"https://www.fool.com/investing/2021/10/21/7-reasons-why-novavax-is-a-no-brainer-pick-over-oc/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1171915283","content_text":"There's no contest between the stock performances of Novavax(NASDAQ:NVAX)and Ocugen(NASDAQ:OCGN)so far this year. Ocugen's share price has skyrocketed roughly seven times more than Novavax's has.\nDoes that make Ocugen the smarter vaccine stock to buy right now? Not at all. Here are seven reasons why Novavax stock is a no-brainer pick over Ocugen.\n1. A path to EUA in the U.S.\nOcugen's share price skyrocketed more than 750% year to date twice in 2021. But much of that massive gain evaporated after the company disclosed in June that it would no longer pursue Emergency Use Authorization (EUA) in the U.S. for COVID-19 vaccine Covaxin.\nThe company opted to go for full approval once the U.S. Food and Drug Administration limited which vaccines would be reviewed under the EUA program. So far, however, Ocugen hasn't begun the late-stage clinical studies that will be required to win full FDA approval.\nMeanwhile, Novavax still has U.S. EUA for its COVID-19 vaccine candidate NVX-CoV2373 as a top priority. The company will be later than it hoped in filing for authorization in the U.S.However, it has the potential to launch in the U.S. much sooner than Ocugen could.\nOcugen still hopes to obtain authorization for Covaxin in Canada. But the U.S. stands as the big prize. And it's a prize for which Novavax clearly has a better opportunity right now.\n2. Supply deals already in hand\nSome investors focus entirely on the approval or authorization process for COVID-19 vaccines. Without supply agreements in place with at least one country, though, any regulatory wins will be hollow victories.\nOcugen doesn't have any supply deals finalized yet. Novavax, on the other hand, already has supply deals in place with the U.S., Canada, the EU, Australia, New Zealand, Japan (through its partner,Takeda), and Gavi, the Vaccine Alliance.\n3. Full rights to its COVID-19 vaccine\nOcugen secured commercialization rights from Bharat Biotech for Covaxin only in the U.S. and Canada. Its terms with Bharat allow the company to keep 45% of the profits from any sales of the COVID-19 vaccine in those two markets.\nNovavax developed NVX-CoV2373 on its own. It retains full rights to the vaccine, although it has partnered with other organizations to target some markets.\n4. A stronger pipeline\nOther than Covaxin, Ocugen doesn't have any other pipeline candidates currently in clinical testing. The company has stated that it plans to advance experimental gene therapy OCU400 into two phase 1/2a clinical trials in 2021, but those studies haven't begun yet.\nNovavax has already reported positive results from a phase 3 study of flu vaccine candidate NanoFlu. It kicked off a phase 1/2 study evaluating a combination of NVX-CoV2373 and NanoFlu in September. The company also has two other clinical-stage candidates -- respiratory syncytial virus vaccine ResVax and an Ebola virus vaccine.\n5. More cash\nCash is extremely important to clinical-stage biotechs. Without enough cash, they can be forced to raise capital to fund operations and expensive clinical trials through dilutive stock offerings.\nAs of June 30, 2021, Ocugen's cash, cash equivalents, and restricted cash totaled $115.8 million. Novavax's cash stockpile stood at $2.1 billion as of the same date.\n6. More potential near-term catalysts\nOcugen really has only one solid potential near-term catalyst: It's awaiting a decision by Health Canada on the authorization of Covaxin. Any wins for the vaccine outside of Canada or the U.S. benefit Bharat but not Ocugen.\nWhat about Novavax? The company hopes to soon win EUAs in India, Indonesia, and the Philippines. Novavax is awaiting Emergency Use Listing from the World Health Organization for NVX-CoV2373. It's also moving toward regulatory filings in the U.K., Europe, Australia, Canada, New Zealand, and the U.S.\n7. A more defensible valuation\nOcugen's impressive performance so far this year has stemmed in large part from the combination of intense online interest and a large number of shares sold short. This makes the stock a good candidate for ashort squeeze. But the company's market cap tops $1.6 billion with analysts expecting Ocugen to only generate around $135 million in revenue next year.\nNovavax, though, could soon see big bucks flowing in if it wins authorizations and approvals for NVX-CoV2373. The company's market cap stands near $12.4 billion. However, with anticipated revenue of $5.5 billion in 2022, that valuation is much more defensible than Ocugen's is.","news_type":1},"isVote":1,"tweetType":1,"viewCount":451,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":862231277,"gmtCreate":1632880318766,"gmtModify":1632880318766,"author":{"id":"4087299128031090","authorId":"4087299128031090","name":"Lemontart","avatar":"https://static.tigerbbs.com/9928a331ddd0127bcf6dfc6e8becce27","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/862231277","repostId":"1121775545","repostType":4,"repost":{"id":"1121775545","pubTimestamp":1632788410,"share":"https://www.laohu8.com/m/news/1121775545?lang=&edition=full","pubTime":"2021-09-28 08:20","market":"sg","language":"en","title":"Electronics demands boost manufacturing performance by 11.2% in August","url":"https://stock-news.laohu8.com/highlight/detail?id=1121775545","media":"Singapore Business","summary":"Thanks to the global semiconductor demand, experts said.\n\nSingapore’s industrial production grew by ","content":"<blockquote>\n <b>Thanks to the global semiconductor demand, experts said.</b>\n</blockquote>\n<p>Singapore’s industrial production grew by 11.2% year-on-year (YoY) in August 2021, according to the latest Economic Development Board (EDB) report. Several experts pointed to a global semiconductor demand as the reason for this growth.</p>\n<p>OCBC Treasury Research puts this performance on the strength of the electronics performance.</p>\n<p>“August manufacturing output surprised on the side at 11.2% YoY (5.7% mom sa), aided by strong electronics performance (15.4% yoy). This is very close to our forecast of 11.3% YoY (7.2% mom sa), but higher than the Bloomberg consensus forecast of 8.2% yoy (3.1% mom sa). Nevertheless, it marked a moderation from July’s revised readings of 16.4% YoY (-2.8% mom sa),” OCBC said.</p>\n<p>OCBC also stated that this performance was even strong enough to offset the weak biomedical cluster performance that had an output shrink of 0.6% YoY,&nbsp;after a steller 78.6% growth in July.</p>\n<p>“Notably, the electronics cluster’s outperformance was underpinned by strong expansion in infocomm and consumer electronics (31.6% YoY), other electronics modules (24.6% YoY) and semiconductors (16.8% YoY). The latter is encouraging given recent news reports of chip shortages being attributed to factories being shut due to COVID outbreaks in Malaysia and Vietnam. Even the US is trying to get more data from US chipmakers to figure out who may be potentially hoarding supplies, so the global chip shortage issue has not been resolved and would be something to still watch going ahead,” it added.</p>\n<p>For its part, UOB said that these clusters, the electronics and precision engineering, had strong performances due to strong global demand for semiconductor-related products</p>\n<p>“Singapore’s electronics and precision engineering clusters remained to be the star performers on the back of strong global demand for semiconductor-related products. The precision engineering cluster rose 22.9% YoY, the fastest pace in three months. According to the media release by the EDB, the higher output of semiconductors and industrial processes equipment lifted the precision engineering cluster, while a strong uptick in semiconductor (+16.8% YoY) production supported the overall electronic segment.</p>\n<p>UOB said, \"The expansion in Singapore’s industrial production is also reinforced by a favourable export backdrop. Whilst non-oil domestic exports decelerated to a growth of 2.7% YoY (-3.6% m/m sa) in August 2021, it still marked the ninth straight month of expansion. Electronic exports rose 16.7% YoY in August 2021, led by shipments of semiconductor-related products such as integrated circuits, diodes, and transistors and disk drives. The positive global export backdrop seen to date is expected to buttress Singapore’s external-facing industries, while higher commodity prices may provide the fillip to overall export value for the year ahead.\"</p>","source":"lsy1618986048053","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Electronics demands boost manufacturing performance by 11.2% in August</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nElectronics demands boost manufacturing performance by 11.2% in August\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-28 08:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://sbr.com.sg/economy/in-focus/electronics-demands-boost-manufacturing-performance-112-in-august><strong>Singapore Business</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Thanks to the global semiconductor demand, experts said.\n\nSingapore’s industrial production grew by 11.2% year-on-year (YoY) in August 2021, according to the latest Economic Development Board (EDB) ...</p>\n\n<a href=\"https://sbr.com.sg/economy/in-focus/electronics-demands-boost-manufacturing-performance-112-in-august\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"STI.SI":"富时新加坡海峡指数"},"source_url":"https://sbr.com.sg/economy/in-focus/electronics-demands-boost-manufacturing-performance-112-in-august","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1121775545","content_text":"Thanks to the global semiconductor demand, experts said.\n\nSingapore’s industrial production grew by 11.2% year-on-year (YoY) in August 2021, according to the latest Economic Development Board (EDB) report. Several experts pointed to a global semiconductor demand as the reason for this growth.\nOCBC Treasury Research puts this performance on the strength of the electronics performance.\n“August manufacturing output surprised on the side at 11.2% YoY (5.7% mom sa), aided by strong electronics performance (15.4% yoy). This is very close to our forecast of 11.3% YoY (7.2% mom sa), but higher than the Bloomberg consensus forecast of 8.2% yoy (3.1% mom sa). Nevertheless, it marked a moderation from July’s revised readings of 16.4% YoY (-2.8% mom sa),” OCBC said.\nOCBC also stated that this performance was even strong enough to offset the weak biomedical cluster performance that had an output shrink of 0.6% YoY, after a steller 78.6% growth in July.\n“Notably, the electronics cluster’s outperformance was underpinned by strong expansion in infocomm and consumer electronics (31.6% YoY), other electronics modules (24.6% YoY) and semiconductors (16.8% YoY). The latter is encouraging given recent news reports of chip shortages being attributed to factories being shut due to COVID outbreaks in Malaysia and Vietnam. Even the US is trying to get more data from US chipmakers to figure out who may be potentially hoarding supplies, so the global chip shortage issue has not been resolved and would be something to still watch going ahead,” it added.\nFor its part, UOB said that these clusters, the electronics and precision engineering, had strong performances due to strong global demand for semiconductor-related products\n“Singapore’s electronics and precision engineering clusters remained to be the star performers on the back of strong global demand for semiconductor-related products. The precision engineering cluster rose 22.9% YoY, the fastest pace in three months. According to the media release by the EDB, the higher output of semiconductors and industrial processes equipment lifted the precision engineering cluster, while a strong uptick in semiconductor (+16.8% YoY) production supported the overall electronic segment.\nUOB said, \"The expansion in Singapore’s industrial production is also reinforced by a favourable export backdrop. Whilst non-oil domestic exports decelerated to a growth of 2.7% YoY (-3.6% m/m sa) in August 2021, it still marked the ninth straight month of expansion. Electronic exports rose 16.7% YoY in August 2021, led by shipments of semiconductor-related products such as integrated circuits, diodes, and transistors and disk drives. The positive global export backdrop seen to date is expected to buttress Singapore’s external-facing industries, while higher commodity prices may provide the fillip to overall export value for the year ahead.\"","news_type":1},"isVote":1,"tweetType":1,"viewCount":445,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":862666435,"gmtCreate":1632876245900,"gmtModify":1632876245900,"author":{"id":"4087299128031090","authorId":"4087299128031090","name":"Lemontart","avatar":"https://static.tigerbbs.com/9928a331ddd0127bcf6dfc6e8becce27","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Ok&nbsp;","listText":"Ok&nbsp;","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/862666435","repostId":"1104845344","repostType":2,"repost":{"id":"1104845344","pubTimestamp":1632874650,"share":"https://www.laohu8.com/m/news/1104845344?lang=&edition=full","pubTime":"2021-09-29 08:17","market":"us","language":"en","title":"Owner-Equivalent Rent Shock On Deck As Actual Rents Surge By Most On Record","url":"https://stock-news.laohu8.com/highlight/detail?id=1104845344","media":"zerohedge","summary":"Another month, another record surge in US rents to a new all time high.\nAccording to theApartment Li","content":"<p>Another month, another record surge in US rents to a new all time high.</p>\n<p>According to theApartment Listnational index, US rents increased by 2.1% from August to September, and although month-over-month growth has slowed slightly from its July peak when the sequential growth rate was 2.6%, rents are still growing much faster than the pre-pandemic trend. Since January of this year, the national median rent has increased by a staggering 16.4%. To put that in context, rent growth from January to September averaged just 3.4% in the pre-pandemic years from 2017-2019.</p>\n<p>While even the smallest cooldown in rent growth is a welcome change for renters, Apartment List's Chris Salviati notes that it’s important to bear in mind that prior to this year, the national index never increased by more than 0.9 percent in a single month, going back to 2017. \"Furthermore, we have now entered the time of year when rents are normally declining due to seasonality in the market. In September of 2018 and 2019, for example, rents fell by 0.1 percent and 0.3 percent, respectively.\"</p>\n<p><img src=\"https://static.tigerbbs.com/8ababcf05160d89248ff02f47a144eac\" tg-width=\"729\" tg-height=\"530\" referrerpolicy=\"no-referrer\">That said, we have a ways to go before US rent - where the median just rose above $1,300 for the first time ever - decline; and with rents rising virtually everywhere, only a few cities still remain cheaper than they were pre-pandemic, and even these remaining discounts are unlikely to persist much longer. At the other end of the spectrum, Apartment List finds<b>22 cities among the 100 largest where rents have increased by more than 25 percent since the start of the pandemic.</b>That said, there are some early signals that tightness in the market may be beginning to ease: the vacancy index ticked up this month for the first time since last April. And in Boise, ID, which has seen the nation’s biggest price increase since the start of the pandemic, rents finally dipped slightly this month.</p>\n<p>The chart below visualizes monthly rent changes in each of the nation’s 100 largest cities from January 2018 to September 2021. The color in each cell represents the extent to which prices went up (red) or down (blue) in a given city in a given month. Bands of dark blue in 2020 represent the large urban centers where rent prices cratered (e.g., New York, San Francisco, Boston), but those bands have quickly turned red as ubiquitous rent growth sweeps the nation in 2021. In 2020, 60 of these cities saw rent prices rise from August to September, but this year, 97 cities got more expensive in September.</p>\n<p><img src=\"https://static.tigerbbs.com/4eab3c0b28f30388b1fc4564f53bbda9\" tg-width=\"617\" tg-height=\"645\" referrerpolicy=\"no-referrer\">In a glimmer of hope for Americans locked out of not only the housing but the rental market, one of the few markets where rents did not increase this month was Boise, ID. Since last March, rents in Boise are up by a staggering 39%, making the city the archetype for rental market disruption amid the pandemic. This month, however, the median rent in Boise fell by 0.1%. While such a small dip certainly doesn’t offer much relief to Boise renters, it may at least signal that the market is finally starting to stabilize. Spokane, WA, another city that has experienced skyrocketing rent growth this year, saw an even more notable decline this month, with rents down 1.8 percent.</p>\n<p><img src=\"https://static.tigerbbs.com/7a29df5c06e6a9f068df656f5ed979c3\" tg-width=\"1280\" tg-height=\"801\" referrerpolicy=\"no-referrer\">Unfortunately, Boise and Spokane represent the exception rather than the rule -- in most of the cities where rents had been growing quickly, that growth is continuing. Tampa, for example, saw rents jump by another 3.9% this month, and the city now ranks 2nd for cumulative rent growth since the start of the pandemic at 36%. Excluding Boise and Spokane, the other eight cities in the chart above experienced rent growth of 3.5%, on average, from August to September, as affordable Sunbelt markets continue to boom. Of particular note, four of the ten cities with the fastest rent growth since last March are suburbs of Phoenix.</p>\n<p>A more tangible indicator that demand destruction may be setting in, is that vacancy rates have posted their first increase since March. Indeed, as Apartment List notes, much of this year’s boom in rent prices can be attributed to a tight market in which more and more households are competing for fewer and fewer vacant units. The vacancy index spiked from 6.2% to 7.1% last April, as many Americans moved in with family or friends amid the uncertainty and economic disruption of the pandemic’s onset. Since then, however, vacancies have been steadily declining. For the past several months, the vacancy index has been hovering just below 4%, significantly lower than the 6% rate that was typical pre-pandemic.</p>\n<p>This month, however, the vacancy index ticked up slightly, from 3.8 percent to 3.9 percent.<b>Although this is a very minor increase, it represents the first increase of any magnitude since last April.</b>While a few more months of data would be needed to confirm an inflection point, if vacancies are back on the rise again, it would signal that tightness in the rental market is finally beginning to ease and that rent growth will also continue to cool.</p>\n<p><img src=\"https://static.tigerbbs.com/a50c20dcd20db5472c3520318c0d2ec1\" tg-width=\"1280\" tg-height=\"777\" referrerpolicy=\"no-referrer\">Finally, where there may be light at the end of the tunnel in real-time data, we have yet to see the pig even enter the python when it comes to the CPI's Owner Equivalent Rent data series. As shown below, the Apartment List data normally has a 4 month lead to the OER series, which means that as actual rents soar by over 15% Y/Y, OER is either going to skyrocket in the coming quarters or the BLS will have to come up with some very fancy hedonic adjustments why rental inflation should exclude, well, rental inflation.</p>\n<p><img src=\"https://static.tigerbbs.com/e8a081c0ce24e0d5801ed8533c04f0a0\" tg-width=\"890\" tg-height=\"612\" referrerpolicy=\"no-referrer\"></p>","source":"lsy1583725640930","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Owner-Equivalent Rent Shock On Deck As Actual Rents Surge By Most On Record</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOwner-Equivalent Rent Shock On Deck As Actual Rents Surge By Most On Record\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-29 08:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.zerohedge.com/markets/owner-equivalent-rent-shock-deck-actual-rents-surge-most-record><strong>zerohedge</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Another month, another record surge in US rents to a new all time high.\nAccording to theApartment Listnational index, US rents increased by 2.1% from August to September, and although month-over-month...</p>\n\n<a href=\"https://www.zerohedge.com/markets/owner-equivalent-rent-shock-deck-actual-rents-surge-most-record\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite","SPY":"标普500ETF",".SPX":"S&P 500 Index",".DJI":"道琼斯"},"source_url":"https://www.zerohedge.com/markets/owner-equivalent-rent-shock-deck-actual-rents-surge-most-record","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1104845344","content_text":"Another month, another record surge in US rents to a new all time high.\nAccording to theApartment Listnational index, US rents increased by 2.1% from August to September, and although month-over-month growth has slowed slightly from its July peak when the sequential growth rate was 2.6%, rents are still growing much faster than the pre-pandemic trend. Since January of this year, the national median rent has increased by a staggering 16.4%. To put that in context, rent growth from January to September averaged just 3.4% in the pre-pandemic years from 2017-2019.\nWhile even the smallest cooldown in rent growth is a welcome change for renters, Apartment List's Chris Salviati notes that it’s important to bear in mind that prior to this year, the national index never increased by more than 0.9 percent in a single month, going back to 2017. \"Furthermore, we have now entered the time of year when rents are normally declining due to seasonality in the market. In September of 2018 and 2019, for example, rents fell by 0.1 percent and 0.3 percent, respectively.\"\nThat said, we have a ways to go before US rent - where the median just rose above $1,300 for the first time ever - decline; and with rents rising virtually everywhere, only a few cities still remain cheaper than they were pre-pandemic, and even these remaining discounts are unlikely to persist much longer. At the other end of the spectrum, Apartment List finds22 cities among the 100 largest where rents have increased by more than 25 percent since the start of the pandemic.That said, there are some early signals that tightness in the market may be beginning to ease: the vacancy index ticked up this month for the first time since last April. And in Boise, ID, which has seen the nation’s biggest price increase since the start of the pandemic, rents finally dipped slightly this month.\nThe chart below visualizes monthly rent changes in each of the nation’s 100 largest cities from January 2018 to September 2021. The color in each cell represents the extent to which prices went up (red) or down (blue) in a given city in a given month. Bands of dark blue in 2020 represent the large urban centers where rent prices cratered (e.g., New York, San Francisco, Boston), but those bands have quickly turned red as ubiquitous rent growth sweeps the nation in 2021. In 2020, 60 of these cities saw rent prices rise from August to September, but this year, 97 cities got more expensive in September.\nIn a glimmer of hope for Americans locked out of not only the housing but the rental market, one of the few markets where rents did not increase this month was Boise, ID. Since last March, rents in Boise are up by a staggering 39%, making the city the archetype for rental market disruption amid the pandemic. This month, however, the median rent in Boise fell by 0.1%. While such a small dip certainly doesn’t offer much relief to Boise renters, it may at least signal that the market is finally starting to stabilize. Spokane, WA, another city that has experienced skyrocketing rent growth this year, saw an even more notable decline this month, with rents down 1.8 percent.\nUnfortunately, Boise and Spokane represent the exception rather than the rule -- in most of the cities where rents had been growing quickly, that growth is continuing. Tampa, for example, saw rents jump by another 3.9% this month, and the city now ranks 2nd for cumulative rent growth since the start of the pandemic at 36%. Excluding Boise and Spokane, the other eight cities in the chart above experienced rent growth of 3.5%, on average, from August to September, as affordable Sunbelt markets continue to boom. Of particular note, four of the ten cities with the fastest rent growth since last March are suburbs of Phoenix.\nA more tangible indicator that demand destruction may be setting in, is that vacancy rates have posted their first increase since March. Indeed, as Apartment List notes, much of this year’s boom in rent prices can be attributed to a tight market in which more and more households are competing for fewer and fewer vacant units. The vacancy index spiked from 6.2% to 7.1% last April, as many Americans moved in with family or friends amid the uncertainty and economic disruption of the pandemic’s onset. Since then, however, vacancies have been steadily declining. For the past several months, the vacancy index has been hovering just below 4%, significantly lower than the 6% rate that was typical pre-pandemic.\nThis month, however, the vacancy index ticked up slightly, from 3.8 percent to 3.9 percent.Although this is a very minor increase, it represents the first increase of any magnitude since last April.While a few more months of data would be needed to confirm an inflection point, if vacancies are back on the rise again, it would signal that tightness in the rental market is finally beginning to ease and that rent growth will also continue to cool.\nFinally, where there may be light at the end of the tunnel in real-time data, we have yet to see the pig even enter the python when it comes to the CPI's Owner Equivalent Rent data series. As shown below, the Apartment List data normally has a 4 month lead to the OER series, which means that as actual rents soar by over 15% Y/Y, OER is either going to skyrocket in the coming quarters or the BLS will have to come up with some very fancy hedonic adjustments why rental inflation should exclude, well, rental inflation.","news_type":1},"isVote":1,"tweetType":1,"viewCount":776,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}